Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed.
Isaacs
J D
JD
Department of Rheumatology, Addenbrooke's NHS Trust, Cambridge, UK.
Hazleman
B L
BL
Chakravarty
K
K
Grant
J W
JW
Hale
G
G
Waldmann
H
H
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009784:Occupational Diseases / Q000209:etiology; D011143:Polyvinyl Chloride / Q000009:adverse effects; D012595:Scleroderma, Systemic / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D012871:Skin Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D011143:Polyvinyl Chloride